Oramed Pharmaceuticals recent Real Value cannot be determined due to lack of data. The prevailing price of Oramed Pharmaceuticals is 1625.0. Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Macroaxis determines value of Oramed Pharmaceuticals from analyzing the company fundamentals such as Revenue of 2.45M, Return On Equity of
(68.54)% and Current Valuation of 240.89M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
|Horizon||30 Days Login to change|
Oramed Pharmaceuticals Total Value AnalysisOramed Pharmaceuticals is now anticipated to have takeover price of 240.89M with market capitalization of 289.25M, debt of 0, and cash on hands of 23.37M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Oramed Pharmaceuticals fundamentals before making investing decisions based on the enterprise value of the company
Oramed Pharmaceuticals Investor InformationThe company recorded loss per share of 0.88. Oramed Pharmaceuticals had not issued any dividends in recent years. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel. Oramed Pharmaceuticals is traded on Tel Aviv Stock Exchange in Israel. To find out more about null contact Nadav Kidron at 972 2 566 0001 or learn more at http://www.oramed.com.
Oramed Pharmaceuticals Asset UtilizationOramed Pharmaceuticals holds negative application of asset of -22.21 pct., making only 0.22 for each of asset held by the company. Inadequate assets utilization implies the company is being less effective with each of asset it holds. In other words assets utilization of Oramed Pharmaceuticals shows how discouraging it operates for each spent on its asset.
Oramed Pharmaceuticals Profitability AnalysisThe company reported revenue of 2.45M. Net Loss for the year was (12.5M) with profit before overhead, payroll, taxes, and interest of 2.27M.
Oramed Pharmaceuticals is Unknown risk asset. Calculation of real value of Oramed Pharmaceuticals is based on 2 months time horizon. Increasing Oramed Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.